The story has been updated to include comments from Exact Sciences' conference call this morning.

NEW YORK (GenomeWeb News) – Exact Sciences today said that revenues for its third quarter were flat, while its net loss narrowed.

The company reported that for the three months ended Sept. 30, revenues remained at $1 million, in line with the average Wall Street estimate. All revenues were derived from licensing fees.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.